GSK drug Lynavoy gets FDA approval

The U.S. Food and Drug Administration (FDA) has approved GSK's new drug, Lynavoy. This medication is indicated for the treatment of pruritus, commonly known as itching, associated with a specific rare liver disorder. The approval offers a new therapeutic option for patients suffering from this debilitating symptom. Lynavoy's efficacy in managing itch in this patient population marks a significant advancement in the treatment landscape for rare liver diseases.